Dyadic International, Inc. a prominent global biotechnology company specializing in advanced microbial platforms for protein development and bioproduction, has recently partnered with Proliant Health and Biologicals (PHB), a leading supplier of purified proteins, to develop and commercialize recombinant albumin. This collaboration aims to provide innovative solutions for diagnostic, nutrition, and cell culture markets, leveraging Dyadic’s expertise in microbial platforms and PHB’s experience in the supply of purified proteins.
Partnership with Proliant Health and Biologicals
Dyadic International and Proliant Health and Biologicals have joined forces to develop and commercialize recombinant albumin. Proliant Health and Biologicals’ extensive experience in the diagnostic, nutrition, and cell culture markets complements Dyadic’s microbial technology platform. By combining their expertise, both companies aim to provide high-quality, cost-effective recombinant albumin for various applications. This collaboration exemplifies Dyadic’s commitment to meeting clinical needs and delivering innovative solutions to the market.
Collaboration with Israel Institute for Biological Research
Dyadic International has also advanced its collaboration with the Israel Institute for Biological Research (IIBR) and Life Science Research Israel (LSRI) to target emerging disease solutions. This partnership allows Dyadic to leverage IIBR’s antibodies and antigens discovery capabilities while utilizing Dyadic’s microbial platform for flexible-scale protein bioproduction. Together, they aim to develop effective treatments and vaccines to address emerging diseases and potential bio-threats. The parties intend to pursue commercialization through collaborative out-licensing initiatives, with the framework subject to a binding agreement.
Partnership with Cygnus Technologies
In another strategic partnership, Dyadic International has joined forces with Cygnus Technologies, a part of Maravai LifeSciences, to enhance quality assurance in biomanufacturing. Dyadic’s proprietary Thermothelomyces heterothallica (formerly Myceliophthora thermophila) C1-cells filamentous fungus is employed for the quantification of Host Cell Proteins (HCP). Cygnus has developed the C1 HCP ELISA Kit, which will be made available to Dyadic and Cygnus customers. This partnership strengthens Dyadic’s commitment to delivering high-quality biomanufacturing solutions.
Conclusion:
Dyadic International’s recent collaborations with Proliant Health and Biologicals, the Israel Institute for Biological Research, and Cygnus Technologies highlight the company’s dedication to advancing protein development and bioproduction to meet clinical needs. These partnerships enable Dyadic to leverage its microbial platform technology and industry expertise while collaborating with leading organizations to provide innovative solutions for various applications, including diagnostic, nutritional, and biomanufacturing markets.
Comments